Prostate-targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice

Nanomedicine

Volumn 7, Issue 9, 2012, Pages 1297-1309

  Yang, Jun ^a,b   Xie, Sheng Xue ^c   Huang, Yiling ^a,d   Ling, Min ^a   Liu, Jihong ^b   Ran, Yali ^a   Wang, Yanlin ^d   Brantley Thrasher, J ^a   Berkland, Cory ^c   Li, Benyi ^a,d  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c UNIVERSITY OF KANSAS   (United States)

^d Three George University School of Medicine   (China)

Author keywords

androgen receptor; aptamer; nanoparticle; prostate cancer; prostate specific membrane antigen; siRNA

Indexed keywords

ANDROGEN RECEPTOR; APTAMER; NANOPARTICLE; POLYGLACTIN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIODEGRADATION; CANCER CELL; CANCER CELL CULTURE; CELL STRAIN LNCAP; CONTROLLED STUDY; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG UPTAKE; GENE SILENCING; HUMAN; HUMAN CELL; MALE; MOUSE; NANOFABRICATION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANIMALS; APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; GENETIC THERAPY; HUMANS; LACTIC ACID; MALE; MICE; MICE, NUDE; NANOPARTICLES; POLYGLYCOLIC ACID; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS;

EID: 84866641974     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.14     Document Type: Article

References (43)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 60(5), 277-300 (2010).
2. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. 23, 8253-8261 (2005).
3. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 24(18), 1967-2000 (2010).
4. Li B and Thrasher JB. Androgen receptor and cellular survival in prostate cancer. Rec. Res. Dev. Cancer 7, 65-89 (2005).
5. Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10 (1), 33-39 (2004).
6. Stanbrough M, Leav I, Kwan PW, Bubley GJ, Balk SP. Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc. Natl Acad. Sci. USA 98(19), 10823-10828 (2001).
7. Liao X, Tang S, Thrasher JB, Griebling TL, Li B. Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol. Cancer Ther. 4(4), 505-515 (2005).
8. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res. 62(4), 1008-1013 (2002).
9. Zhang L, Johnson M, Le KH et al. Interrogating androgen receptor function in recurrent prostate cancer. Cancer Res. 63(15), 4552-4560 (2003).
10. Li TH, Zhao H, Peng Y, Beliakoff J, Brooks JD, Sun Z. A promoting role of androgen receptor in androgen-sensitive and-insensitive prostate cancer cells. Nucleic Acids Res. 35, 2767-2776 (2007).
11. Snoek R, Cheng H, Margiotti K et al. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin. Cancer Res. 15(1), 39-47 (2009).
12. Cheng H, Snoek R, Ghaidi F, Cox ME, Rennie PS. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res. 66(21), 10613-10620 (2006).
13. Sun A, Tang J, Terranova PF, Zhang X, Thrasher JB, Li B. Adeno-associated virus-delivered short hairpin-structured RNA for androgen receptor gene silencing induces tumor eradication of prostate cancer xenografts in nude mice: a preclinical study. Int. J. Cancer 126(3), 764-774 (2010).
14. Compagno D, Merle C, Morin A et al. SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas. PLoS ONE 2(10), e1006 (2007).
15. Azuma K, Nakashiro K, Sasaki T et al. Antitumor effect of small interfering RNA targeting the androgen receptor in human androgen-independent prostate cancer cells. Biochem. Biophys. Res. Commun. 391(1), 1075-1079 (2010).
16. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 56(11), 1649-1659 (2004).
17. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7(11), 653-664 (2010).
18. Sengupta S, Eavarone D, Capila I et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436(7050), 568-572 (2005).
19. Wright GL Jr, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol. Oncol. 1(1), 18-28 (1995).
20. Katsogiannou M, Peng L, Catapano CV, Rocchi P. Active-targeted nanotherapy strategies for prostate cancer. Curr. Cancer Drug Targets 11(8), 954-965 (2011).
21. Lupold SE, Hicke BJ, Lin Y, Coffey DS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 62, 4029-4033 (2002).
22. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550-553 (2002).
23. Shanmugam I, Cheng G, Terranova PF, Thrasher JB, Thomas CP, Li B. Serum/glucocorticoid-induced protein kinase-1 facilitates androgen receptor-dependent cell survival. Cell Death Differ. 14(12), 2085-2094 (2007).
24. Bala I, Hariharan S, Kumar MN. PLGA nanoparticles in drug delivery: the state of the art. Crit. Rev. Ther. Drug Carrier Syst. 21(5), 387-422 (2004).
25. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl Acad. Sci. USA 105(45), 17356-17361 (2008).
26. Farokhzad OC, Cheng J, Teply BA et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl Acad. Sci. USA 103(16), 6315-6320 (2006).
27. Cheng J, Teply BA, Sherifi I et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28(5), 869-876 (2007).
28. Dhar S, Kolishetti N, Lippard SJ, Farokhzad OC. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc. Natl Acad. Sci. USA 108(5), 1850-1855 (2011).
29. Gu F, Zhang L, Teply BA et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc. Natl Acad. Sci. USA 105(7), 2586-2591 (2008).
30. Sanna V, Roggio AM, Posadino AM et al. Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactide-co- glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies. Nanoscale Res. Lett. 6(1), 260 (2011).
31. Kim D, Jeong YY, Jon S. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano. 4(7), 3689-3696 (2010).
32. Yu MK, Kim D, Lee IH, So JS, Jeong YY, Jon S. Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles. Small 7(15), 2241-2249 (2011).
33. Ni X, Zhang Y, Ribas J et al. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J. Clin Invest. 121(6), 2383-2390 (2011).
34. Dassie JP, Liu XY, Thomas GS et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat. Biotechnol. 27(9), 839-849 (2009).
35. Li Y, Ogris M, Pelisek J, Röedl W. Stability and release characteristics of poly(d,l-lactide-co-glycolide) encapsulated CaPi-DNA coprecipitation. Int. J. Pharm. 269(1), 61-70 (2004).
36. Chittasupho C, Shannon L, Siahaan TJ, Vines CM, Berkland C. Nanoparticles targeting dendritic cell surface molecules effectively block T cell conjugation and shift response. ACS Nano. 5(3), 1693-1702 (2011).
37. Chittasupho C, Manikwar P, Krise JP, Siahaan TJ, Berkland C. cIBR effectively targets nanoparticles to LFA-1 on acute lymphoblastic T cells. Mol. Pharm. 7(1), 146-155 (2010).
38. Chittasupho C, Xie SX, Baoum A, Yakovleva T, Siahaan TJ, Berkland CJ. ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. Eur. J. Pharm Sci. 37(2), 141-150 (2009).
39. Li B, Sun A, Youn H et al. Conditional Akt activation promotes androgen-independent progression of prostate cancer. Carcinogenesis 28(3), 572-583 (2007).
40. Venier-Julienne MC, Benoît JP. Preparation, purification and morphology of polymeric nanoparticles as drug carriers. Pharm. Acta Helv. 71(2), 121-128 (1996).
41. Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. J. Biomater. Sci. Polym. Ed. 17(3), 247-289 (2006).
42. Mohamed F, van der Walle CF. Engineering biodegradable polyester particles with specific drug targeting and drug release properties. J. Pharm Sci. 97(1), 71-87 (2008).
43. Baoum A, Dhillon N, Buch S, Berkland C. Cationic surface modification of PLG nanoparticles offers sustained gene delivery to pulmonary epithelial cells. J. Pharm. Sci. 99(5), 2413-2422 (2010).